Free Trial

Avadel Pharmaceuticals (AVDL) Stock Price, News & Analysis

Avadel Pharmaceuticals logo
$10.60 -0.03 (-0.28%)
As of 03:34 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Avadel Pharmaceuticals Stock (NASDAQ:AVDL)

Key Stats

Today's Range
$10.60
$11.03
50-Day Range
$8.81
$11.25
52-Week Range
$6.38
$17.30
Volume
427,149 shs
Average Volume
1.34 million shs
Market Capitalization
$1.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.33
Consensus Rating
Buy

Company Overview

Avadel Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

AVDL MarketRank™: 

Avadel Pharmaceuticals scored higher than 50% of companies evaluated by MarketBeat, and ranked 571st out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Avadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Avadel Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Avadel Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($0.51) to $0.06 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Avadel Pharmaceuticals is -40.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Avadel Pharmaceuticals is -40.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Avadel Pharmaceuticals has a P/B Ratio of 14.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Avadel Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    13.78% of the float of Avadel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Avadel Pharmaceuticals has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in Avadel Pharmaceuticals has recently increased by 19.02%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Avadel Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Avadel Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.78% of the float of Avadel Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Avadel Pharmaceuticals has a short interest ratio ("days to cover") of 9.1.
  • Change versus previous month

    Short interest in Avadel Pharmaceuticals has recently increased by 19.02%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Avadel Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.04 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Avadel Pharmaceuticals this week, compared to 5 articles on an average week.
  • Search Interest

    3 people have searched for AVDL on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Avadel Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.20% of the stock of Avadel Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    69.19% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Avadel Pharmaceuticals' insider trading history.
Receive AVDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AVDL Stock News Headlines

AI Frenzy Could Send ‘EarnPhone’ Soaring
The hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and searches — are feeding the next wave of AI innovation. Big Tech is harvesting it. Mode Mobile is giving it back to you. They are creating a user-powered data economy that shares the upside, and +50M users have already generated +$325M in earnings. This isn't a theory… Mode’s 32,481% revenue growth from 2019-2022 landed them the #1 spot on Deloitte’s 2023 list of fastest growing companies in software, and they’ve secured the Nasdaq ticker $MODE ahead of a potential IPO. The offering could close any moment now. AI breakthroughs are everywhere, but these models need your data to survive. Invest in the company that allows you to share in the profits from yours.
AVDL Avadel Pharmaceuticals plc - Seeking Alpha
See More Headlines

AVDL Stock Analysis - Frequently Asked Questions

Avadel Pharmaceuticals' stock was trading at $10.51 on January 1st, 2025. Since then, AVDL shares have increased by 2.9% and is now trading at $10.82.

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) announced its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.02. The company's revenue was up 93.2% compared to the same quarter last year.
Read the conference call transcript
.

Avadel Pharmaceuticals' top institutional investors include Wealth Effects LLC (2.43%), Investors Asset Management of Georgia Inc. GA ADV (0.14%), VIRGINIA RETIREMENT SYSTEMS ET Al (0.02%) and KLP Kapitalforvaltning AS (0.02%). Insiders that own company stock include Peter J Thornton, Thomas S Mchugh, Geoffrey Michael Glass, Geoffrey Michael Glass, Linda Palczuk, Mark Anthony Mccamish and Gregory J Divis.
View institutional ownership trends
.

Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Avadel Pharmaceuticals investors own include Advanced Micro Devices (AMD), Bank of America (BAC), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Cisco Systems (CSCO) and Netflix (NFLX).

Company Calendar

Last Earnings
5/07/2025
Today
7/30/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AVDL
CIK
1012477
Employees
70
Year Founded
2015

Price Target and Rating

High Price Target
$30.00
Low Price Target
$12.00
Potential Upside/Downside
+69.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.27)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$48.83 million
Net Margins
-13.58%
Pretax Margin
-13.72%
Return on Equity
-36.07%
Return on Assets
-16.30%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.73
Quick Ratio
2.33

Sales & Book Value

Annual Sales
$194.45 million
Price / Sales
5.38
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.77 per share
Price / Book
14.05

Miscellaneous

Outstanding Shares
96,739,000
Free Float
91,709,000
Market Cap
$1.05 billion
Optionable
Optionable
Beta
1.42

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:AVDL) was last updated on 7/30/2025 by MarketBeat.com Staff
From Our Partners